Skip to main content

COVID-19 and radiation oncology: the experience of a two-phase plan within a single institution in central Italy

Abstract

Background

COVID-19 in Italy has led to the need to reorganize hospital protocols with a significant risk of interruption to cancer treatment programs. In this report, we will focus on a management model covering the two phases of the COVID-19 emergency, namely lockdown-phase I and post-lockdown-phase II.

Methods

The following steps were taken in the two phases: workload during visits and radiotherapy planning, use of dedicated routes, measures for triage areas, management of suspected and positive COVID-19 cases, personal protective equipment, hospital environments and intra-institutional meetings and tumor board management. Due to the guidelines set out by the Ministry of Health, oncological follow-up visits were interrupted during the lockdown-phase I; consequently, we set about contacting patients by telephone, with laboratory and instrumental exams being viewed via telematics. During the post-lockdown-phase II, the oncological follow-up clinic reopened, with two shifts operating daily.

Results

By comparing our radiotherapy activity from March 9 to May 4 2019 with the same period in 2020 during full phase I of the COVID-19 emergency, similar results were achieved. First radiotherapy visits, Simulation Computed Tomography and Linear Accelerator treatments amounted to 123, 137 and 151 in 2019 compared with 121, 135 and 170 in 2020 respectively. There were no cases of COVID-19 positivity recorded either in patients or in healthcare professionals, who were all negative to the swab tests performed.

Conclusion

During both phases of the COVID-19 emergency, the planned model used in our own experience guaranteed both continuity in radiotherapy treatments whilst neither reducing workload nor interrupting treatment and, as such, it ensured the safety of cancer patients, hospital environments and staff.

Introduction

The rapid and uncontrolled spread of COVID-19 in some regions and provinces of northern Italy led to the declaration of partial and complete lockdown of the entire country by the national government between March 8 and March 22, 2020 and this phase, known here as Phase I, lasted from March 9 to May 3, 2020 [1,2,3]. From May 4, 2020 the so-called Phase II was approved, and consisted in a gradual deceleration to Phase I as a result of a decline to the epimedic's curve [4] (Fig. 1). On June 7, 2020 Italy recorded a total of 234,998 COVID-19 cases wherein: 168,640 had recovered, 32,459 were in home self-isolation and 33,899 deceased [5]. Until the middle of April, the number of patients hospitalized in intensive and non-intensive care units progressively increased as a result of the consequent need for a complete reorganization of hospital infrastructures. The territorial heterogeneity of the COVID-19 trend brought about a decisive and dramatic prevalence in areas of northern Italy and a more contained incidence in areas of central and southern Italy (Fig. 2) [5].

Fig. 1
figure1

Trends and projections of Italy’s epidemic report. The purple line represents the number of new real daily cases (to the right of the reference scale); the light blue line represents the persistence conditions of the lockdown. In the background (to the left of the scale), the cumulative day-per-day deaths (red), recoveries (blue), patients currently positive and requiring admission to intensive units (orange), non-intensive unit admissions (yellow) and home self-isolation (green) (modified by https://ilsegnalatore.info/)

Fig. 2
figure2

COVID-19 cases divided into individual Italian regions (modified by https://ilsegnalatore.info/)

In Abruzzo, a region of central Italy with a population of 1,304,970 inhabitants, a total number of 3265 (1.39%) cases were recorded on June 7, 2020 with a spike in infections taking place on March 29, 2020, and resulted in hospitals operating at maximum capacity on April 3, 2020, with 418 deaths, 2215 recoveries and 632 in home self-isolation [6] (Fig. 3). Therefore, although with smaller numbers, the Abruzzo region also underwent an important distress and COVID-19 centered reorganization of hospital activities with the interruption on March 13, 2020 of all planned medical and surgical activities with the exception of oncology and hematology services which clinicians judged non-deferrable. In fact, when regarding cytostatic, radiation oncology or immunological treatments, the Ministry of Health emphasized to local Health Authorities the need to guarantee these "life-saving" treatments to all patients and to plan dedicated routes and spaces for those patients being treated as well as the availability of all necessary individual protective devices and equipment [7, 8]. Furthermore, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) implemented a document to make radiotherapy operating procedures homogeneous throughout the ongoing COVID-19 emergency [9] and conducted a targeted national survey [10]. To this regard, several experiences have been published on the management of radiation therapy during the pandemic [11,12,13,14,15,16,17]. We aim to report here our particular experience in the organizational planning of radiotherapy during the two phases of the COVID-19 emergency, lockdown phase I and post-lockdown phase II. It was in doing so that we were able to guarantee treatment continuity whilst maintaining the safety of cancer patients and healthcare personnel within the framework of a complete COVID-19 reorganization at the University Hospital of Chieti.

Fig. 3
figure3

Trends and projections of the Abruzzo epidemic report. The purple line represents the number of new real daily cases (to the right of the reference scale); the light blue line represents the persistence conditions of the lockdown. In the background (scale on the left), the cumulative day-per-day deaths (red) and recoveries (blue), patients currently positive and requiring admission to intensive units (orange), non-intensive unit admissions (yellow) and home self-isolation (green) (modified by https://ilsegnalatore.info/)

Materials and methods

The Radiation Oncology Center of Chieti is one of four radiotherapy centers in the Abruzzo region and is equipped with two Linear Accelerators (Linacs) that both operate during two daily shift patterns between 8.00 am and 8.30 pm; Simulation Computed Tomography (Simul CT) and clinical dosimetry facilities that work at normal capacity within the working hours of 8.00 am and 2.00 pm; a clinic room dedicated to first radiotherapy visits and a clinic room dedicated to the scheduled follow-up visit of cancer patients both with working hours between 8.00 am and 2.00 pm; and finally an oncological day-hospital unit for the management of concurrent radio-chemotherapy treatments.

The radiotherapy staff consist of 11 doctors, 14 technicians, 3 dedicated physicists, 5 nurses, 2 administrative staff members, a socio-health operator, and a secretary. The center is also a university site with a specialization school in Radiation Oncology and a total of 7 resident doctors and a staff operating across 44 units. An average of around 800 patients are treated each year. Table 1 shows the measures planned for radiotherapy activities between the Hospital Management and Hospital Quality Office respectively in both lockdown phase I and post-lockdown phase II of the COVID-19 pandemic.

Table 1 Planned actions implemented for radiotherapy activities in lockdown Phase I and in post-lockdown Phase II in the experience of Chieti Radiation Oncology department

Results

By comparing the center’s treatment activity under ordinary routine conditions, within the period March 9–May 4, 2019, with the same time interval during full lockdown phase I of the COVID-19 emergency, March 9–May 4, 2020, no changes were observed in the number of services performed. Significantly, in 2019, 123 first radiotherapy visits were performed, with 137 new patients prepared for Simul CT and 151 patients treated on Linear Accelerators. In the same period in 2020 and during the critical phase of the pandemic, the action plans set up allowed for 121 first radiotherapy visits to be performed, as well as 135 new patients to be prepared for Simul CT and 170 patients to be treated on Linear Accelerators (Table 2). Dose hypofractionation was predominantly used in breast, prostate and palliative treatment. There were no cases of COVID-19 positivity recorded in patients or in healthcare professionals throughout both phase I and phase II. During the week of May 25 to May 31, 2020 all staff members of the Center underwent oropharyngeal and nasopharyngeal swab testing with negative results in all 42 examined. Two staff members have not been examined, due to their being in maternity and illness periods respectively since last year.

Table 2 Comparison of the number of radiotherapy performances in the lockdown Phase I (March 9–May4, 2020) with the same period of 2019 in ordinary clinical activity

Discussion

The COVID-19 pandemic that hit Italy had serious repercussions on the national hospital system which subsequently had to reorganize its assistance network with the introduction of COVID-19 centered hospitals and with a prevalence of intensive and sub-intensive care units. Many internal and surgical departments were reconverted and dedicated to the management of COVID-19 within only a few weeks, with the radiological and laboratory diagnostic activities seriously involved in these plans. Although witnessing more contained case numbers than the regions and provinces of northern Italy, the main hospitals of the Abruzzo region and, specifically in our experience, the University Hospital of Chieti, were reorganized to conform to COVID-19 measures in only a short period of time. This particular situation carried a double risk due to the potential of delays or interruptions in to oncological therapies, which, despite being a "life-saving" treatment, could have been hazardous to patients who are often already frail and also at high risk of infection themselves as well as to carers and health personnel alike. Several scientific documents and papers published on the subject represented an important reference point especially in the first phase of the emergency [11,12,13,14,15,16,17] and with particular regard to the use of protection systems, triage procedures and the use of hypofractionation schemes. In particular, a national survey conducted by the Italian Society of Radiotherapy and Clinical Oncology and, prior even to this, a survey of the radiotherapy centers of the Lombardy region, the region most affected by COVID-19 [10, 14], both reported and supported the measures, implemented for the new rearrangement of centers, the workloads necessary and the COVID-19 cases found. Most of the measures adopted and reported in the surveys are in line with the planned approach undertaken in our particular experience with the exception of the "working from home scheme" which cannot be performed at our center due to the absence of dedicated technology.

During both lockdown and post-lockdown phases, we performed a full maintenance of simul-CT, dosimetry activities and radiotherapy treatment, preferring the incorporation of hypofractionated schemes. Both Linac and simul-CT disinfection was guaranteed during each shift as well as strict hand hygiene with the use of hydroalcoholic solutions and disposable gloves mandatory to all staff, both before and after each clinical and technical procedure.

For personnel and patients alike, temperature (required < 37.5 °C) was checked prior to entering the Department, as well as the mandatory wearing of surgical masks. In the triage area, only four patients at a time were permitted entry, with a distance of at least one meter. Respiratory symptoms, dysgeusia and anosmia and ocular disorders, such as conjunctivitis, were also checked; whilst furthermore, a dedicated hospital questionnaire on any potential contact with suspected COVID-19 patients was issued and completed by all patients.

In accordance with the Ministry of Health guidelines, oncological follow-up visits were interrupted during the lockdown-phase I: consultation by telephone was made with patients, with laboratory and instrumental exams viewed via telematics. During phase II, the oncological follow-up clinic reopened, with two shifts daily (8.00 am–1.00 pm and 2.00 pm–5.00 pm), and appointment spacing of one patient every 45 min.

Overall, the clinical activity of the Italian centers saw a reduction of < 10% in 32% of cases and of 10–30% in 30.4% of cases. In our particular experience, the clinical activity during the lockdown phase was comparable to that of the same period of 2019 and, except for a rescheduling of the oncological follow-up visits, there were no interruptions in treating patients nor reduction in radiotherapy preparation or treatment of newly diagnosed cancer patients. The national survey also reports 29.6% of the positive or suspect cases treated in Italian centers. No positive or suspicious cases were found in our experience during phase I and phase II. However, the differences shown in the reduction of workloads and the number of positive or suspect patients reported in the national survey highlight the predominance of the COVID-19 cases in the regions of northern Italy and, in particular, Lombardy where a reduction of 10–50% in radiotherapy was registered, but also in greater organizational awareness due to the increase of national and international guidelines emerging on the subject during this period and in the detailed recommendations on individual tumor pathologies treated using hypofractionated regimens [22,23,24,25,26]. In our experience, dose hypofractionation has been used in breast, prostate and palliation cancers.

Conclusion

The organizational model implemented in our experience, respectively, during the lockdown phase I and the post-lockdown phase II ensured an optimal continuity of radiotherapy workflow without reducing workload or interrupting the radiation therapy cycles, as well as the safety of cancer patients, the hospital environments and the radiation oncology staff. It is therefore recommended that each Radiation Oncology center customize its organizational model for the management of COVID-19 based on the characteristics and directives used in the University Hospital of Chieti and on the specific features of the center in terms of equipment, staff and hospital environments.

Availability of supporting data

Not applicable.

Abbreviations

AIRO:

Italian association of radiotherapy and clinical oncology

Linacs:

Linear accelerators

Simul CT:

Simulation computed tomography

References

  1. 1.

    Gazzetta Ufficiale della Repubblica Italiana, Serie n. 59, 08 Marzo 2020.https://www.gazzettaufficiale.it/eli/gu/2020/03/08/59/sg/pdf.

  2. 2.

    Gazzetta Ufficiale della Repubblica Italiana, Serie n. 64, 11 Marzo 2020. https://www.gazzettaufficiale.it/eli/gu/2020/03/11/64/sg/pdf.

  3. 3.

    Gazzetta Ufficiale della Repubblica Italiana, Serie n. 76, 22 Marzo 2020. https://www.gazzettaufficiale.it/eli/gu/2020/03/22/76/sg/pdf.

  4. 4.

    Gazzetta Ufficiale della Repubblica Italiana, Serie n. 109, 28 Aprile 2020.https://www.gazzettaufficiale.it/eli/gu/2020/04/28/109/sg/pdf.

  5. 5.

    Department of Civil Protection—Presidency of the Council of Ministers. Dipartimento della Protezione Civile, Presidenza del Consiglio dei Ministri. https://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1.

  6. 6.

    Abruzzo Region. https://www.regione.abruzzo.it/content/coronavirus-abruzzo-dati-aggiornati-all%E2%80%998-giugno-casi-positivi-3265.

  7. 7.

    Ministero della Salute-Direzione Generale della Programmazione sanitaria. “Raccomandazioni per la gestione dei pazienti oncologici e oncoematologici in corso di emergenza da COVID-19 redatte su iniziativa del Comitato Tecnico-Scientifico della Protezione Civile”. REGIONE.LAZIO.REGISTRO UFFICIALE.I.0214498.10-03-2020. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=73635&parte=1%2520&serie=null.

  8. 8.

    The Royal College of Radiologists. Timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions, fourth edition |The Royal College of Radiologists. 2019; published online Jan. https://www.rcr.ac.uk/publication/timely-delivery-radical-radiotherapy-guidelines-management-unscheduled-treatment. Accessed March 7, 2020.

  9. 9.

    Documento di Indirizzo per la Valutazione e la Gestione del Rischio dei Pazienti e degli Operatori nei Reparti di Radioterapia Oncologica in corso di Diffusione del COVID-19–Associazione Italiana di Radioterapia e Oncologia Clinica (AIRO); V. 1-AIRO, 17 Marzo 2020. https://www.radioterapiaitalia.it/wp-content/uploads/2020/03/v-2-Documento-AIRO-COVID-19-24-03-2020.pdf.

  10. 10.

    Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale E Bastia M, Catalano G, Filippi AR, Franco P, Gambacorta MA, Genovesi D, Iatì G, Magli A, Marafioti L, Meattini I, Merlotti A, Mignogna M, Musio D, Pacelli R, Pergolizzi S, Tombolini V, Trovò M, Ricardi U, Magrini SM, Corvò R, Donato V; AIRO (Italian Association of Radiotherapy and Clinical Oncology). COVID-19 outbreak and cancer radiotherapy disruption in Italy: survey endorsed by the Italian association of radiotherapy and clinical oncology (AIRO). RadiotherOncol. 2020; 149:89–93. https://doi.org/10.1016/j.radonc.2020.04.061.

  11. 11.

    Simcock R, Thomas TV, Estes C, Filippi AR, Katz MA, Pereira IJ, Saeed H. COVID-19: Global radiation oncology's targeted response for pandemic preparedness. ClinTranslRadiatOncol. 2020;22:55–68. https://doi.org/10.1016/j.ctro.2020.03.009.

    Article  Google Scholar 

  12. 12.

    Filippi AR, Russi E, Magrini SM, Corvò R. Letter from Italy: first practical indications for radiation therapy departments during COVID-19 outbreak. Int J RadiatOncolBiolPhys. 2020;107:597–9. https://doi.org/10.1016/j.ijrobp.2020.03.007.

    Article  Google Scholar 

  13. 13.

    Pezzulla D, Macchia G, Taccari F, Sticca G, Deodato F. Radiotherapy in southern Italy at the time of COVID-19: options for radiation oncology units. Int J Gynecol Cancer. 2020;30:917–9. https://doi.org/10.1136/ijgc-2020-001523.

    Article  PubMed  Google Scholar 

  14. 14.

    Jereczek-Fossa BA, Palazzi MF, Soatti CP, Cazzanigra LF, Ivaldi GB, Pepa M, Amadori M, Antognoni P, Arcangeli S, Buffoli A, Beltramo G, Berlinghieri S, Bignardi M, Bracelli S, Bruschieri L, Castiglioni S, Catalano G, Di Muzio N, Fallai C, Fariselli L, Filippi AR, Gramaglia A, Italia C, Lombardi F, Magrini SM, Nava S, Orlandi E, Pasinetti N, Sbicego EL, Scandolaro L, Scorsetti M, Stiglich F, Tonoli S, Tortini R, Valdagni R, Vavassori V, Marvaso G; CODRAL (Board of Directors of Radiation Oncology Departments in Lombardy) network. COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy. ClinOncol (R CollRadiol) 2020, 32: e160–1. https://doi.org/10.1016/j.clon.2020.04.007.

  15. 15.

    Valenza F, Papagni G, Marchianò A, Daidone MG, DeBraud F, Colombo MP, Frignani A, Galmozzi G, Ladisa V, Pruneri G, Salvioni R, Spada P, Torresani M, Rinaldi O, Manfredi S, Votta M, Apoloni G. Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS-Istituto Nazionale dei Tumori di Milano. Tumori J. 2020;106:193–202. https://doi.org/10.1177/0300891620923790.

    CAS  Article  Google Scholar 

  16. 16.

    Meattini I, Franco P, Belgioia L, Boldrini L, Botticella A, De Santis MC, Marvaso G, Montesi G, Parisi S, Triggiani L, Lambertini M, Livi L. Radiation therapy during the coronavirus disease 2019 (COVID-19) pandemic in Italy: a view of the nation's young oncologists. ESMO Open. 2020;5:e000779. https://doi.org/10.1136/esmoopen-2020-000779.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Montesi G, Di Biase S, Chierchini S, Pavanato G, VirdisGE, Contato E,Mandoliti G. Radiotherapy during COVID-19 pandemic. How to create a no fly zone: a Northern Italy Experience. RadiolMed 2020, 125:600–603. https://doi.org/10.1007/s11547-020-01217-8.

  18. 18.

    Procedura per la Gestione di "Coronavirus Disease 2019" (COVID-19), ASL 2 Lanciano-Vasto-Chieti, Documento Aziendale N° PGSQA 107, 16/04/2020. https://lnx.asl2abruzzo.it/asl/attachments/article/274/REV2-PGSQA107-Procedura-per-la-gestione-della-Coronavirus-Disease-2019-(COVID-19)-File-Unico.pdf.

  19. 19.

    Informativa sul trattamento dei dati personali per l’accesso alle strutture della ASL Lanciano Vasto Chieti a fini di prevenzione da COVID-19—Rilievo di temperatura corporea (ai sensi dell’Art. 13 del Regolamento UE 679/2016), Documento Aziendale N° INFIOSQA64-01, 28/05/2020. https://lnx.asl2abruzzo.it/a/attachments/article/3112/INFIOSQA64-01%2520Informativa%2520trattamento%2520dati%2520personali%2520accesso%2520strutture%2520dell~.pdf.

  20. 20.

    Indicazioni ad Interim per un utilizzo razionale delle protezioni per infezione da SARS-COV-2 nelle attività sanitarie e sociosanitarie (Assistenza a soggetti affetti da COVID-19) nell'attuale scenario emergenziale SARS-COV-2; Gruppo di Lavoro Istituto Superiore di Sanità (ISS) "Prevenzione e Controllo delle Infezioni"; Rapporto ISS COVID-19—N. 2/2020 Rev. https://www.iss.it/documents/20126/0/Rapporto+ISS+COVID+2_+Protezioni_REV.V6.pdf/740f7d89-6a28-0ca1-8f76-368ade332dae?t=1585569978473.

  21. 21.

    Attività della Radioterapia Oncologica nella fase II dell'emergenza COVID-19, ASL Lanciano-Vasto-Chieti, Documento Aziendale N° IORADIOCH-01, 18/06/2020. https://lnx.asl2abruzzo.it/asl/.

  22. 22.

    Zaorsky NG, Yu JB, McBridge SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate cancer radiotherapy recommendations in response to COVID-19. AdvRadiatOncol. 2020. https://doi.org/10.1016/j.adro.2020.03.010.

    Article  Google Scholar 

  23. 23.

    Combs SE, Belka C, Niyazi M, Corradini S, Pigorsch S, Wilkens J, Grosu AL, Guckenberger M, Ganswindt U, Bernhardt D. First statement on preparation for theCOVID-19 pandemic in large German Speaking University-based radiation oncology departments. RadiatOncol. 2020;15:74. https://doi.org/10.1186/s13014-020-01527-1.

    CAS  Article  Google Scholar 

  24. 24.

    Coles CE, Aristei C, Bliss J, BoersmaL, Brunt AM, Chatterjee S,Hanna G, Jagsi R, Kaidar Person O, Kirby A, Mjaaland I, Meattini I, Luis A M, Marta G N, Offersen B, Poortmans P, Rivera S. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. ClinOncol (R CollRadiol) 2020;32:279–81. https://doi.org/10.1016/j.clon.2020.03.006.

  25. 25.

    Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, Brizel D, Budach W, Caudell J, Corry J, Corvo R, Evans M, Garden AS, Giralt J, Gregoire V, Harari PM, Harrington K, Hitchcock YJ, Johansen J, Kaanders J, Koyfman S, Langendijk JA, Le QT, Lee N, Margalit D, Mierzwa M, Porceddu S, Soong YL, Sun Y, Thariat J, Waldron J, Yom SS. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys. 2020;107:618–27. https://doi.org/10.1016/j.ijrobp.2020.04.016.

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Yahalom J, Dabaja B, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, Illidge T, Qi S, Wirth A, Specht L. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135:1829–32. https://doi.org/10.1182/blood.2020006028.

Download references

Acknowledgements

The authors thank the Department of Neuroscience, Imaging and Clinical Sciences of “G. D’Annunzio” University for its support.

Funding

Not applicable.

Author information

Affiliations

Authors

Contributions

LC, CR, ADP, LAU, MTa, AV, AA, MDT, MTr, MN and DG designed and coordinated the study and the analysis. CR, FP, GCe, LG, DF, FCDG, CB, MB, GCa, SM, CT, DM and SS collected the data. MDF, ADN and NC performed main data analysis and provided pictures elaboration. LC, CR, ADP, LAU, MTa, AV, AA, MDT, MTr, MN and DG drafted the manuscript. MBDS, ATS, TS, AM, SC, CDA and NV critically revised the study and the manuscript. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Luciana Caravatta.

Ethics declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Yes.

Competing interests

All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caravatta, L., Rosa, C., Di Sciascio, M.B. et al. COVID-19 and radiation oncology: the experience of a two-phase plan within a single institution in central Italy. Radiat Oncol 15, 226 (2020). https://doi.org/10.1186/s13014-020-01670-9

Download citation

Keywords

  • Coronavirus
  • COVID-19
  • Pandemic
  • Radiation oncology
  • Radiotherapy
  • SARS-CoV-2